Moleculin Biotech, Inc. (MBRX) fell -26.07% with the finishing price of $2.07 in Friday Trading Session. With Latest loss move, stock price showed -44.80% downward in value from one year high price and revealed 193.04% upward in value from its one year low price.
In the recent week Moleculin Biotech, Inc. stock price volatility was noted 12.43% while for the last month volatility was seen at 7.96%. Its Average True Range (ATR) shows a number of 0.25.
The 10.50% rising picture painted by the trends generated around 20 SMAs. The established market sentiment toward the stock has created a trading environment which can suitably be described as optimistic.
There has been rising move seen around 50 SMAs. The stock price is showing 11.93% distance above 50 SMA. On the surface, it seems as the higher the 50-day moving average goes, the more bullish the market is (and the lower it goes, the more bearish). In practice, however, the reverse is true. The 50-day moving average is perceived to be the dividing line between a stock that is technically healthy and one that is not. Furthermore, the percentage of stocks above their 50-day moving average helps determine the overall health of the market. Many market traders also use moving averages to determine profitable entry and exit points into specific securities.
Moleculin Biotech, Inc. (MBRX) has demonstrated rising trend based on recent movement of 200 SMA with 11.74% during the course of recent market activity. This trend reveals recent direction. The current direction of 200 SMA is upward. When the price over the last 200 days is moving with increasing trend, look for buy opportunities and when it shows decreasing trend the price is below the last 200 days, look for sell opportunities.
The current value of the RSI is 54.78. The relative strength index (RSI) readings highlights overbought above 70 and oversold below 30.
The stock price changed 23.21% in the past week. Shares of the company have performed 29.37% over the last three months and moved 71.07% over the last 12- months.
Analysts contributed mean rating at 2. This recommendation scale based between 1 and 5. Analysts offer the company with a rating of 3 would be a sign of a Hold rating. Analysts pass on shares a rating of 1 or 2 would be signifying a Buy. A rating of 4 or 5 would tip to a Sell suggestion.